ClinicalTrials.gg
RecruitingNCT06995417STOP-HNCUpdated Nov 17, 2026

Discontinuation of Tobacco Dependence in Smoking Patients With Squamous Cell Carcinoma of the Head-neck District: Multicenter Prospective Observational Study

An observational study in Cancer of Head and Neck, sponsored by Azienda Ospedaliero-Universitaria Careggi. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Azienda Ospedaliero-Universitaria Careggi · Observational

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 17, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 134 studies in Head and Neck Neoplasms with a site in Italy — 43 open to participants now, 57 under way, 6 of them phase 3. Head and Neck Neoplasms · Italy.

Planned enrollment
19th of 37
200 · median 200
Started
2025
with 11 others
Observational
37 of 134
24 open now
Primary completion
2025-12
later than 13 of 56 live
Registered
119th of 134
by date

Among the 134 studies in Head and Neck Neoplasms with a site in Italy, this one is the 19th largest by planned enrollment of the 37 observational ones that give a count, is one of 12 that started in 2025, is one of 37 observational ones, reaches primary completion later than 13 of the 56 other live ones, and was the 119th registered.

Head and Neck Neoplasms

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

43 of the 134 studies in Head and Neck Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Head and Neck Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

The primary objective of our study is to evaluate the effectiveness of a standardized clinical practice counseling strategy for promoting post-diagnosis smoking cessation among patients with SCCHN. Efficacy will be measured as the percentage of patients who succeed in sustained smoking cessation ("sustained quitters," see below) at 6+1 months after enrollment, i.e., after the initiation of anti-smoking counseling.

03

Conditions studied

  • Cancer of Head and Neck

Keywords

  • Cancer Head&Neck
  • Smoker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will be patients with SCCHN who are active smokers, or have quit smoking for less than 30 days, at the time of initiation of the process (visits and instrumental examinations) that led to the cancer diagnosis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with SCCHN tumors of the oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, and paranasal sinuses.
  • Patients older than 18 years of age with SCCHN of these sites who are candidates for surgical/radiotherapy (RT)/radiochemotherapy (RTCT) treatment with curative intent (primary treatment).
  • Patients with SCCHN who are active smokers, or have quit smoking for less than 30 days, at the time of initiation of the process (visits and instrumental tests) that led to the diagnosis of cancer

Exclusion criteria

Exclusion criteria

  • Patients with SCCHN cancer who have quit smoking for more than 30 days at the time of initiation of the diagnostic process.
  • Patients using only e-cigarettes at the time of initiation of the treatment process.
  • Patients with non-SCCHN cancer in recurrent stage and not eligible for curative purpose therapy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Interventions

  • OtherSmoking counseling

    The investigator, upon enrollment, will initiate a standardized strategy from clinical practice: the investigator will conduct brief counseling ("minimal advice") using the administration of of a questionnaire that will include, in addition to questions about current and past, the administration of the Fagerstrom test to measure physical dependence on nicotine and questions to investigate intention to quit smoking (Mondor test)

06

What researchers measure

Primary outcomes

  1. Effectiveness of a standardized counseling strategy in clinical practice to promote smoking cessation

    The primary objective of our study is to evaluate the effectiveness of a standardized clinical practice counseling strategy for promoting post-diagnosis smoking cessation among patients with SCCHN. Efficacy will be measured as the percentage of patients who succeed in sustained smoking cessation ("sustained quitters," see below) at 6+1 months after enrollment, i.e., after the initiation of anti-smoking counseling.

    Time frame: 6+1 months from enrollment, i.e., initiation of anti-smoking counseling.

07

Study locations

1 of 1 sites recruiting
  • Azienda Ospedaliera Careggi
    Florence, Firenze 51134, Italy
    Recruiting
    • LORENZO LIVI · Contactlorenzo.livi@unifi.it · +390557947019
    • Pierluigi Bonomo, MEDICAL DOCTOR · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Dec 2025, 5 months.

Of 215 non-industry observational studies under Head and Neck Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 144. This study's 5 months is below that.

Counting every sponsor, half of 237 studies reached it within 71 months; a quarter within 29 and three quarters within 144.

Start moved once since we started tracking on Sep 25, 2026: Jun 2025 → Jul 2025, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2025
First posted
May 29, 2025
StartActual
Jul 10, 2025was Jun 2025
Primary completionActual
Dec 15, 2025
CompletionEst.
May 2030
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
Azienda Ospedaliera Careggi is now Recruiting
Nov 17, 2026
Start date
Jun 2025→Jul 10, 2025 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    Azienda Ospedaliera Careggi is now Recruiting
    Start date Jun 2025→Jul 10, 2025 (now actual)
    + 3 other changes: verification date, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06995417
Lead sponsor
Azienda Ospedaliero-Universitaria Careggi
Responsible party
Lorenzo Livi (Full Professor, Azienda Ospedaliero-Universitaria Careggi) — Principal investigator
First posted
May 29, 2025
Start date
Jul 10, 2025
Primary completion
Dec 15, 2025
Completion
May 2030 (estimated)
Last update
Nov 17, 2026

Study contacts

PIERLUIGI PB BONOMO, MEDICAL DOCTOR
Contact
bonomopierlu@gmail.com
+390557947010
LUCIA PAOLINI
Contact
rt.datamanager@sbsc.unifi.it
+393393830695
LORENZO LL LIVI, MEDICAL DOCTOR
principal investigator · AOU Careggi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion